{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:44:00Z","timestamp":1789591440816,"version":"build-2803163510"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.gene.2026.150201","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:22:43Z","timestamp":1778084563000},"page":"150201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The VEGF\/VEGFR axis in triple-negative breast cancer: a comprehensive review of therapeutic strategies"],"prefix":"10.1016","volume":"1001","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5610-0869","authenticated-orcid":false,"given":"Muhammed Ihsan","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar","family":"Atalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guzide","family":"Satir-Basaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2026.150201_b0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1523-1755.2000.07718.x","article-title":"Role of vascular endothelial growth factor in diabetic vascular complications","volume":"77","author":"Aiello","year":"2000","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.gene.2026.150201_b0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semcancer.2020.06.019","article-title":"Emerging roles of long non-coding RNAs in breast cancer biology and management","volume":"72","author":"Amelio","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.gene.2026.150201_b0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41598-020-80081-y","article-title":"Targeting mTOR and DNA repair pathways in residual triple-negative breast cancer after neoadjuvant chemotherapy","volume":"11","author":"Anand","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.gene.2026.150201_b0020","first-page":"1233","article-title":"Understanding and treating triple-negative breast cancer","volume":"22","author":"Anders","year":"2008","journal-title":"Oncology"},{"key":"10.1016\/j.gene.2026.150201_b0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3816\/CBC.2009.s.008","article-title":"Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer","volume":"9","author":"Anders","year":"2009","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0030","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-10-0939","article-title":"Poly(ADP-ribose) polymerase inhibition: targeted therapy for triple-negative breast cancer","volume":"16","author":"Anders","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gene.2026.150201_b0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11010-017-3244-1","article-title":"Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy","volume":"444","author":"Babyshkina","year":"2018","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.gene.2026.150201_b0040","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","article-title":"Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets","volume":"4","author":"Balko","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.gene.2026.150201_b0045","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bjc.6602374","article-title":"Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer","volume":"92","author":"Bando","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0050","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2026.150201_b0055","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0060","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.3390\/ijms21155294","article-title":"VEGF-A in cardiomyocytes and heart diseases","volume":"21","author":"Braile","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gene.2026.150201_b0065","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000438613","article-title":"Comparative profiling of triple-negative breast carcinoma tissue glycoproteome by sequential purification of glycoproteins and stable isotope labeling","volume":"38","author":"Chen","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.gene.2026.150201_b0070","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1002\/ijc.24900","article-title":"Tumor suppressor function of Rab25 in triple-negative breast cancer","volume":"15","author":"Cheng","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1124\/pharmrev.122.000665","article-title":"Newly developed targeted therapies against the androgen receptor in triple-negative breast cancer: a review","volume":"75","author":"Choupani","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.gene.2026.150201_b0080","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","article-title":"Prognostic and predictive factors in early-stage breast cancer","volume":"9","author":"Cianfrocca","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.gene.2026.150201_b0085","first-page":"925","article-title":"Lymphatic microvessels density, VEGF-C, and VEGFR-3 expression in invasive lobular breast carcinoma","volume":"54","author":"Ciobanu","year":"2013","journal-title":"Rom. J. Morphol. Embryol."},{"key":"10.1016\/j.gene.2026.150201_b0090","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(07)70074-8","article-title":"Triple-negative breast cancer: therapeutic options","volume":"8","author":"Cleator","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0095","unstructured":"ClinicalTrials.gov, Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02."},{"key":"10.1016\/j.gene.2026.150201_b0100","first-page":"93","article-title":"Triple-negative breast cancer: treatment challenges and solutions","volume":"8","author":"Collignon","year":"2016","journal-title":"Breast Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0105","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12195-025-00866-x","article-title":"Strain promotes triple-negative breast cancer proliferation and migration via VEGFR-2","volume":"18","author":"Cooper","year":"2025","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.gene.2026.150201_b0110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2026.150201_b0115","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-018-4697-y","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer: a review","volume":"169","author":"Costa","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.gene.2026.150201_b0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/annonc\/mds196","article-title":"Emerging targeted therapies in triple-negative breast cancer","volume":"23","author":"Crown","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103916","article-title":"Synthesis and molecular docking study of new pyrazole derivatives as potent anti-breast cancer agents targeting VEGFR-2 kinase","volume":"101","author":"Dawood","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.gene.2026.150201_b0135","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41419-020-02926-8","article-title":"M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2","volume":"11","author":"Dong","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.gene.2026.150201_b0140","first-page":"3","article-title":"Deregulation of VEGFR-2 and PDGFR expression and microvascular density in a triple-negative model of canine malignant mammary tumors with lymph node or lung metastasis","volume":"6","author":"dos Anjos","year":"2019","journal-title":"Vet. Sci."},{"key":"10.1016\/j.gene.2026.150201_b0145","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/ijc.27632","article-title":"Targeted therapy for triple-negative breast cancer: where are we?","volume":"131","author":"Duffy","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.17219\/acem\/58784","article-title":"Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: association with lymph node metastasis","volume":"26","author":"Ero\u011flu","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.gene.2026.150201_b0155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10549-013-2793-6","article-title":"Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy","volume":"143","author":"Fan","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.gene.2026.150201_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2025.1711415","article-title":"Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation","volume":"16","author":"Fan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.gene.2026.150201_b0165","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/ATVBAHA.108.179663","article-title":"Vascular endothelial growth factor","volume":"29","author":"Ferrara","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.gene.2026.150201_b0170","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.gene.2026.150201_b0175","first-page":"183","article-title":"Current advances in biomarkers for targeted therapy in triple-negative breast cancer","volume":"8","author":"Fleisher","year":"2016","journal-title":"Breast Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.04.014","article-title":"Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2","volume":"215","author":"Gao","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.gene.2026.150201_b0185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13058-020-01354-y","article-title":"Phase II study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer","volume":"22","author":"Garrido-Castro","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.gene.2026.150201_b0190","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bjc.6602824","article-title":"Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells","volume":"93","author":"Garvin","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0195","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40262-017-0587-4","article-title":"PARP inhibitors in the treatment of triple-negative breast cancer","volume":"57","author":"Geenen","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.gene.2026.150201_b0200","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ctrv.2018.06.005","article-title":"Androgen receptor in triple-negative breast cancer: a potential target for the targetless subtype","volume":"68","author":"Gerratana","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.gene.2026.150201_b0205","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/annonc\/mdp492","article-title":"Triple-negative breast cancer\u2014current status and future directions","volume":"20","author":"Gluz","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0210","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.currproblcancer.2016.09.004","article-title":"Targeting the androgen receptor in triple-negative breast cancer","volume":"40","author":"Gucalp","year":"2016","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116097","article-title":"Design and synthesis of novel (S)-naproxen hydrazide-hydrazones as potent VEGFR-2 inhibitors and their evaluation in vitro\/in vivo breast cancer models","volume":"37","author":"Han","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.gene.2026.150201_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.578095","article-title":"New perspectives for resistance to PARP inhibitors in triple-negative breast cancer","volume":"10","author":"Han","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0225","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/gb-2005-6-2-209","article-title":"The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease","volume":"6","author":"Holmes","year":"2005","journal-title":"Genome Biol."},{"key":"10.1016\/j.gene.2026.150201_b0230","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/ijc.28829","article-title":"Multicenter phase II study of apatinib in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"135","author":"Hu","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2011-S1-01","article-title":"Triple-negative breast cancer: an unmet medical need","volume":"16","author":"Hudis","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.gene.2026.150201_b0240","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2741\/4847","article-title":"Epigenetic alterations in cancer","volume":"25","author":"Ilango","year":"2020","journal-title":"Front Biosci"},{"key":"10.1016\/j.gene.2026.150201_b0245","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.ejca.2008.09.034","article-title":"What is triple-negative breast cancer?","volume":"44","author":"Irvin","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0250","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","article-title":"TBCRC009: a multicenter phase II clinical trial of platinum monotherapy in metastatic triple-negative breast cancer","volume":"33","author":"Isakoff","year":"2015","journal-title":"J. Clin.Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0255","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/PPO.0b013e3181d24ff7","article-title":"Triple-negative breast cancer: role of specific chemotherapy agents","volume":"16","author":"Isakoff","year":"2010","journal-title":"Cancer J."},{"key":"10.1016\/j.gene.2026.150201_b0260","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrclinonc.2009.130","article-title":"An overview of small-molecule inhibitors of VEGFR signaling","volume":"6","author":"Ivy","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0265","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jconrel.2020.07.003","article-title":"A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer","volume":"326","author":"Jain","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.gene.2026.150201_b0270","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2217\/pgs-2017-0117","article-title":"Triple-negative breast cancer and the potential for targeted therapy","volume":"18","author":"Jhan","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.gene.2026.150201_b0275","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3892\/ijo.2023.5521","article-title":"P2Y2R-mediated transactivation of VEGFR2 through Src phosphorylation is associated with radiotherapy-resistant triple-negative breast cancer cells","volume":"62","author":"Jin","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0280","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/gcc.21922","article-title":"Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis","volume":"51","author":"Johansson","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0285","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11658-022-00344-6","article-title":"The role of epigenetic modifications in drug resistance and treatment of breast cancer","volume":"27","author":"Karami Fath","year":"2022","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.gene.2026.150201_b0290","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled phase II trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0295","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/GCO.0000000000000243","article-title":"Cyclin-dependent kinase pathways as targets for women\u2019s cancer treatment","volume":"28","author":"Konecny","year":"2016","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.gene.2026.150201_b0300","doi-asserted-by":"crossref","first-page":"R140","DOI":"10.1186\/bcr3345","article-title":"Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancer","volume":"14","author":"Kosaka","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.gene.2026.150201_b0305","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.18632\/oncotarget.26638","article-title":"Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer","volume":"10","author":"Kourti","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.gene.2026.150201_b0310","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An overview of triple-negative breast cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.gene.2026.150201_b0315","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11864-017-0506-9","article-title":"Role of platinum in early-stage triple-negative breast cancer","volume":"18","author":"La Belle","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0320","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrneurol.2016.88","article-title":"Vascular endothelial growth factor: a neurovascular target in neurological diseases","volume":"12","author":"Lange","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.gene.2026.150201_b0325","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3892\/mmr.2016.5430","article-title":"Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer","volume":"14","author":"Lebok","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.gene.2026.150201_b0330","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.3390\/cancers12082122","article-title":"Effects of cancer stem cells in triple-negative breast cancer and brain metastasis: challenges and solutions","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.gene.2026.150201_b0335","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.1021\/acs.jmedchem.1c00678","article-title":"Discovery, synthesis, and evaluation of highly selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor for the potential treatment of metastatic triple-negative breast cancer","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.gene.2026.150201_b0340","first-page":"1","article-title":"Targeted therapeutic strategies for triple-negative breast cancer","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114423","article-title":"HIF-1\u03b1 inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting PlGF\/VEGFR1-induced macrophage polarization","volume":"161","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.gene.2026.150201_b0350","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-022-01310-7","article-title":"Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0355","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11912-021-01041-x","article-title":"Role of platinums in triple-negative breast cancer","volume":"23","author":"Lynce","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.gene.2026.150201_b0360","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11864-019-0682-x","article-title":"Targeted therapies for triple-negative breast cancer","volume":"20","author":"Lyons","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0365","doi-asserted-by":"crossref","first-page":"9360","DOI":"10.3390\/ijms24119360","article-title":"The mechanism of DNA methylation and miRNA in breast cancer","volume":"24","author":"Ma","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gene.2026.150201_b0370","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdw562","article-title":"A randomized adaptive phase II\/III study of buparlisib combined with paclitaxel for the treatment of HER2-negative advanced breast cancer (BELLE-4)","volume":"28","author":"Mart\u00edn","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0375","doi-asserted-by":"crossref","first-page":"60712","DOI":"10.18632\/oncotarget.10858","article-title":"Triple-negative breast cancer: shedding light onto the role of PI3K\/AKT\/mTOR pathway","volume":"7","author":"Massihnia","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.gene.2026.150201_b0380","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1158\/1078-0432.CCR-13-0583","article-title":"New strategies for triple-negative breast cancer\u2014deciphering the heterogeneity","volume":"20","author":"Mayer","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gene.2026.150201_b0385","first-page":"455","article-title":"Vascular endothelial growth factor (VEGF) \u2013 key factor in normal and pathological angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Rom. J. Morphol. Embryol."},{"key":"10.1016\/j.gene.2026.150201_b0390","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/jcb.22584","article-title":"A novel intracellular isoform of VEGFR-1 activates Src and promotes cell invasion in MDA-MB-231 breast cancer cells","volume":"110","author":"Mezquita","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.gene.2026.150201_b0395","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.1038\/s41598-018-25526-1","article-title":"All-trans-retinoic acid activates the pro-invasive Src\u2013YAP\u2013interleukin 6 axis in triple-negative MDA-MB-231 breast cancer cells while cerivastatin reverses this action","volume":"8","author":"Mezquita","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.gene.2026.150201_b0400","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.2147\/OTT.S126051","article-title":"Targeting the androgen receptor in triple-negative breast cancer: current perspectives","volume":"10","author":"Mina","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.gene.2026.150201_b0405","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3390\/cancers13051027","article-title":"A novel bispecific antibody targeting EGFR and VEGFR2 is effective against triple-negative breast cancer via multiple mechanisms of action","volume":"13","author":"Mohan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.gene.2026.150201_b0410","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4048\/jbc.2019.22.e39","article-title":"Druggable molecular targets for the treatment of triple-negative breast cancer","volume":"22","author":"Nakhjavani","year":"2019","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0415","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer","volume":"8","author":"Nedeljkovic","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.gene.2026.150201_b0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065217","article-title":"Vascular endothelial growth factor receptor-1 activation promotes migration and invasion of breast cancer cells through epithelial\u2013mesenchymal transition","volume":"8","author":"Ning","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.gene.2026.150201_b0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.618839","article-title":"IL-1\u03b2 promotes vasculogenic mimicry of breast cancer cells through p38\/MAPK and PI3K\/Akt signaling pathways","volume":"11","author":"Nisar","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0430","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/bmm-2017-0398","article-title":"Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker","volume":"12","author":"O\u2019Conor","year":"2018","journal-title":"Biomark. Med."},{"key":"10.1016\/j.gene.2026.150201_b0435","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa1011418","article-title":"Iniparib plus chemotherapy in metastatic triple-negative breast cancer","volume":"364","author":"O\u2019Shaughnessy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2026.150201_b0440","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/annonc\/mdz177","article-title":"FAIRLANE: a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer","volume":"30","author":"Oliveira","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0445","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2018.04.010","article-title":"The role of PARP inhibition in triple-negative breast cancer: unraveling the wide spectrum of synthetic lethality","volume":"67","author":"Papadimitriou","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.gene.2026.150201_b0450","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/cancers11070965","article-title":"Targeting cancer stem cells in triple-negative breast cancer","volume":"11","author":"Park","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.gene.2026.150201_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155174","article-title":"Beyond genetics: exploring the role of epigenetic alterations in breast cancer","volume":"254","author":"Prabhu","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.gene.2026.150201_b0460","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/bjc.2014.444","article-title":"Predicting response and survival in chemotherapy-treated triple-negative breast cancer","volume":"111","author":"Prat","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0465","first-page":"1757","article-title":"Lymphatic microvessel density, VEGF-C, and VEGFR-3 expression in different molecular types of breast cancer","volume":"31","author":"Raica","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.gene.2026.150201_b0470","first-page":"85","article-title":"Breast cancer: a review of the literature","volume":"35","author":"Richie","year":"2003","journal-title":"Insur. Med."},{"key":"10.1016\/j.gene.2026.150201_b0475","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10549-010-0758-6","article-title":"Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer","volume":"120","author":"Ryd\u00e9n","year":"2010","journal-title":"BreastCancer Res. Treat."},{"key":"10.1016\/j.gene.2026.150201_b0480","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.3390\/ijms24043601","article-title":"High VEGFR3 expression reduces doxorubicin efficacy in triple-negative breast cancer","volume":"24","author":"Ruiz","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gene.2026.150201_b0485","doi-asserted-by":"crossref","first-page":"287","DOI":"10.31083\/j.fbl2908287","article-title":"Epigenetic modulations in breast cancer: an emerging paradigm in therapeutic implications","volume":"29","author":"Sarkar","year":"2024","journal-title":"Front Biosci"},{"key":"10.1016\/j.gene.2026.150201_b0490","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0495","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2026.150201_b0500","first-page":"1719","article-title":"Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage","volume":"28","author":"Schmidt","year":"2008","journal-title":"Anticancer Res"},{"key":"10.1016\/j.gene.2026.150201_b0505","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.3390\/biomedicines9121789","article-title":"FAK regulates VEGFR2 expression and promotes angiogenesis in triple-negative breast cancer","volume":"9","author":"Shiau","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.gene.2026.150201_b0510","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10456-006-9055-8","article-title":"Vascular endothelial growth factor receptor-1 (VEGFR-1\/Flt-1): a dual regulator for angiogenesis","volume":"9","author":"Shibuya","year":"2006","journal-title":"Angiogenesis"},{"key":"10.1016\/j.gene.2026.150201_b0515","first-page":"519","article-title":"Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family","volume":"5","author":"Shibuya","year":"1990","journal-title":"Oncogene"},{"issue":"2023","key":"10.1016\/j.gene.2026.150201_b0520","first-page":"17","article-title":"Cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.gene.2026.150201_b0525","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/annonc\/mdn395","article-title":"Platinum-based chemotherapy in triple-negative breast cancer","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0530","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3390\/cancers14102569","article-title":"Breast cancer\u2014epidemiology, classification, pathogenesis and treatment","volume":"14","author":"Smolarz","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.gene.2026.150201_b0535","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/746749","article-title":"Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor a","author":"Srabovic","year":"2013","journal-title":"Int. J. Breast Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0540","first-page":"915","article-title":"Structure and function of VEGF receptors","volume":"61","author":"Stuttfeld","year":"2009","journal-title":"Life"},{"key":"10.1016\/j.gene.2026.150201_b0545","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.bmcl.2014.03.042","article-title":"Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ER-\u03b1 and VEGFR-2","volume":"24","author":"Tang","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.gene.2026.150201_b0550","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ejmech.2016.04.029","article-title":"Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ER-\u03b1 and VEGFR-2 as anti-breast cancer agents","volume":"118","author":"Tang","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.gene.2026.150201_b0555","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12013-014-0459-6","article-title":"Breast cancer: epidemiology and etiology","volume":"72","author":"Tao","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.gene.2026.150201_b0560","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/OTT.S67673","article-title":"Triple-negative breast cancer: new perspectives for targeted therapies","volume":"8","author":"Tomao","year":"2015","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.gene.2026.150201_b0565","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.gene.2026.150201_b0570","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0575","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0580","first-page":"106","article-title":"Current approaches in treatment of triple-negative breast cancer","volume":"12","author":"Wahba","year":"2015","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.gene.2026.150201_b0585","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.gene.2026.150201_b0590","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1307860","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.gene.2026.150201_b0595","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10549-012-1977-9","article-title":"Ellagic acid exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer","volume":"134","author":"Wang","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.gene.2026.150201_b0600","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1084\/jem.20180439","article-title":"KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer","volume":"215","author":"Wang","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.gene.2026.150201_b0605","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/cells8091010","article-title":"Eribulin synergistically increases anti-tumor activity of an mTOR inhibitor by inhibiting pAKT\/pS6K\/pS6 in triple-negative breast cancer","volume":"8","author":"Wen","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.gene.2026.150201_b0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","article-title":"Vascular endothelial growth factors and angiogenesis in eye disease","volume":"22","author":"Witmer","year":"2003","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.gene.2026.150201_b0615","doi-asserted-by":"crossref","first-page":"71","DOI":"10.22514\/ejgo.2025.122","article-title":"Downregulation of TSPAN1 inhibits angiogenesis in triple-negative breast cancer cells by regulating the PI3K\/Akt signaling pathway","volume":"46","author":"Wu","year":"2025","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.gene.2026.150201_b0620","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/ijc.21865","article-title":"The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma","volume":"119","author":"Wu","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0625","doi-asserted-by":"crossref","unstructured":"Yadav, B.S., Sharma, S.C., Chanana, P., Jhamb, S., Systemic treatment strategies for triple-negative breast cancer. World J. Clin. Oncol. 5 (2014) 125\u2013133. [PMID: 24829859 DOI: 10.5306\/wjco.v5.i2.125].","DOI":"10.5306\/wjco.v5.i2.125"},{"key":"10.1016\/j.gene.2026.150201_b0630","first-page":"1","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.gene.2026.150201_b0635","first-page":"1","article-title":"Resibufogenin suppresses triple-negative breast cancer angiogenesis by blocking VEGFR2-mediated signaling pathway","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.gene.2026.150201_b0640","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","article-title":"The impact of VEGF on cancer metastasis and systemic disease","volume":"86","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.gene.2026.150201_b0645","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.gene.2026.150201_b0650","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/onco.13583","article-title":"A phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor-positive metastatic triple-negative breast cancer","volume":"26","author":"Yuan","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.gene.2026.150201_b0655","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1039\/D0DT00380H","article-title":"Two novel chiral tetranucleate copper-based complexes: crystal structures, nanoparticles, and inhibiting angiogenesis and the growth of human breast cancer by regulating the VEGF\/VEGFR2 signal pathway in vitro","volume":"49","author":"Zhang","year":"2020","journal-title":"Dalton Trans."},{"key":"10.1016\/j.gene.2026.150201_b0660","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12609-023-00493-3","article-title":"Metastatic triple-negative breast cancer","volume":"15","author":"Zhang","year":"2023","journal-title":"Curr. Breast Cancer Rep."},{"key":"10.1016\/j.gene.2026.150201_b0665","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1038\/onc.2014.257","article-title":"VEGF drives cancer-initiating stem cells through VEGFR-2\/Stat3 signaling to upregulate Myc and Sox2","volume":"34","author":"Zhao","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.gene.2026.150201_b0670","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/1535-7163.MCT-15-0501","article-title":"Preclinical evaluation of a novel orally available SRC\/Raf\/VEGFR2 inhibitor, SKLB646, in the treatment of triple-negative breast cancer","volume":"15","author":"Zheng","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.gene.2026.150201_b0675","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fendo.2015.00159","article-title":"The emerging regulation of VEGFR-2 in triple-negative breast cancer","volume":"6","author":"Zhu","year":"2015","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.gene.2026.150201_b0680","article-title":"Platinum-based systemic therapy in triple-negative breast cancer","volume":"1877","author":"Zhu","year":"2022","journal-title":"BBA Rev. Cancer"},{"key":"10.1016\/j.gene.2026.150201_b0685","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers13040713","article-title":"Epigenetic alterations in triple-negative breast cancer: the critical role of extracellular matrix","volume":"13","author":"Zolota","year":"2021","journal-title":"Cancers"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111926002118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111926002118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:41:15Z","timestamp":1779338475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111926002118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":136,"alternative-id":["S0378111926002118"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2026.150201","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The VEGF\/VEGFR axis in triple-negative breast cancer: a comprehensive review of therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2026.150201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150201"}}